title: The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
abstract: The inflammation-mediated comorbidities in myelofibrosis (MF) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. JAK1-2 inhibitors in MF-patients reduce constitutional symptoms and splenomegaly, but also taget autoimmune and inflammation-mediated comorbidities.
authors.affiliation: Department of Hematology, Roskilde University Hospital, Roskilde Denmark ; Institute for Inflammation Research (IIR), Department of Infectious Diseases and Rheumatology, Copenhagen University Hospital Rigshospitalet, Denmark.
authors.forename: Mads Emil
authors.initials: ME
authors.lastname: Bjørn
authors.affiliation: Department of Hematology, Roskilde University Hospital, Roskilde Denmark.
authors.forename: Hans Carl
authors.initials: HC
authors.lastname: Hasselbalch
keywords: Autoimmunity; comorbidities; inflammation; myelofibrosis; myeloproliferative neoplasm; remission; ruxolitinib